Kwangdong Pharmaceutical

Vitamin C drink brand presented as "drinkable vitamin C".

Traditional herbal product the company presents alongside Ssanghwatang under its founding idea of modernizing traditional medicine with science.

Pegunigalsidase alfa enzyme replacement therapy for adults with Fabry disease, made by Italy's Chiesi; after a 2023 exclusive Korean distribution agreement, it was approved in Korea in May 2026.

Retinitis pigmentosa gene therapy developed by Ocugen of the U.S.; Kwangdong acquired exclusive Korean development and commercialization rights under a 2025 agreement. The Phase 3 liMeliGhT trial is ongoing.

Diagnostic device specialist acquired in July 2024.

Received Korean marketing approval for the Fabry disease treatment Elfabrio (pegunigalsidase alfa), the first Fabry treatment in Korea using a plant-cell-derived recombinant protein.

With MSD Korea, its co-promotion partner for the 21-valent pneumococcal conjugate vaccine CAPVAXIVE, announced a year-round awareness campaign on adult pneumococcal disease prevention.